Amryt Pharma PLC Holding(s) in Company (3067I)
11 Agosto 2021 - 6:36AM
UK Regulatory
TIDMAMYT
RNS Number : 3067I
Amryt Pharma PLC
11 August 2021
TR-1: S tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the underlying Amryt Pharma PLC
issuer of existing shares to which voting GB00BKLTQ412
rights are attached (ii) :
--------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights
---------------------
An acquisition or disposal of financial instruments
---------------------
An event changing the breakdown of voting rights
---------------------
Other (please specify)(iii) : Increase in the total number of voting X
rights
---------------------
3. Details of person subject to the notification obligation (iv)
Name UBS Asset Management - O'Connor
UBS Group AG
City and country of registered office Zürich, Switzerland
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v)
Name
--------------------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------------------
5. Date on which the threshold was 6 August 2021
crossed or reached (vi) :
--------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 10 August 2021
--------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting Total of both Total number
rights attached rights in % (8.A + of voting rights
to shares through 8.B) of issuer (vii)
(total of financial
8. A) instruments
(total of 8.B
1 + 8.B 2)
---------------- ---------------- --------------------------------- ---------------------
Resulting
situation
on the date on
which
threshold was Below Below
crossed Notifiable Notifiable Below Notifiable
or reached Threshold Threshold Threshold 307'118'662
---------------- ---------------- --------------------------------- ---------------------
Position of
previous
notification (if
applicable) 0.00% 6.12% 6.12%
---------------- ---------------- --------------------------------- ---------------------
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares (ix)
ISIN code
(if possible)
Direct Indirect Direct Indirect
(Art 9 of (Art 10 of (Art 9 of Directive (Art 10 of Directive
Directive Directive 2004/109/EC) (DTR5.1) 2004/109/EC)
2004/109/EC) 2004/109/EC) (DTR5.2.1)
(DTR5.1) (DTR5.2.1)
----------------
GB00BKLTQ412 Below Below Notifiable
Notifiable Threshold
Threshold
---------------- ---------------- --------------------------------- ---------------------
SUBTOTAL 8. A Below Notifiable Threshold Below Notifiable Threshold
---------------------------------- --------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date (x) Conversion rights that may rights
Period (xi) be acquired if
the instrument
is
exercised/converted.
---------------- ---------------- --------------------------------- ---------------------
US03217L1061
---------------- ---------------- --------------------------------- ---------------------
SUBTOTAL 8. Below Notifiable Below Notifiable
B 1 Threshold Threshold
---------------- --------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date (x) Conversion cash voting rights rights
instrument Period settlement
(xi) (xii)
----------------- ---------------- --------------- ----------------
SUBTOTAL 8.B.2
--------------- ----------------
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by
any natural person or legal entity and does not control any other undertaking(s)
holding directly or indirectly an interest in the (underlying) issuer
(xiii)
Full chain of controlled undertakings through which the voting rights X
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (xiv) (please add additional
rows as necessary)
Name (xv) % of voting % of voting rights Total of both if
rights if it through financial it equals or is
equals or is instruments if it higher than the
higher than equals or is higher notifiable threshold
the notifiable than the notifiable
threshold threshold
------------------- ------------------------ ------------------------
UBS Group AG
------------------- ------------------------ ------------------------
UBS AG
------------------- ------------------------ ------------------------
UBS Americas Holding LLC
------------------- ------------------------ ------------------------
UBS Americas Inc.
------------------- ------------------------ ------------------------
UBS Asset Management (Americas)
Inc.
------------------- ------------------------ ------------------------
UBS O'Connor LLC
------------------- ------------------------ ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights
will be held
11. Additional information (xvi)
Place of completion Opfikon, Switzerland
Date of completion 10.08.2021
---------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLFZGMRLMKGMZG
(END) Dow Jones Newswires
August 11, 2021 05:36 ET (09:36 GMT)
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
Notícias em tempo-real sobre Amryt Pharma Plc da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Amryt Pharma Plc
